Drug intelligence / Profile preview

lobaplatin + vinorelbine

Development stage: Unknown
Lead developer: Degussa
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of lobaplatin, a platinum-based antineoplastic agent, and vinorelbine, a semi-synthetic vinca alkaloid. Lobaplatin forms DNA adducts that inhibit DNA synthesis and trigger apoptosis, while vinorelbine acts as an anti-mitotic agent by interfering with tubulin polymerization and microtubule formation during cell division. This combination has shown synergistic cytotoxic activity in vitro and enhanced antitumor activity in non-small cell lung cancer xenografts.

Targets

TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on lobaplatin + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lobaplatin + vinorelbine.

Explore the full profile